During the past decade, Tochigi Cancer Center conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 7 clinical trials were completed, i.e. on average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tochigi Cancer Center" #1 sponsor was "Japan Clinical Oncology Group" with 5 trials, followed by "Haruhiko Fukuda" with 4 trials sponsored, "Amgen" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Sumitomo Pharma Oncology, Inc." with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tochigi Cancer Center" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 9 trials as a collaborator, "Japan Agency for Medical Research and Development" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Japan Clinical Oncology Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Tochigi Cancer Center" are "Gastric Cancer" (3 trials), "Colorectal Cancer" (2 trials), "Multiple Myeloma" (2 trials), "Advanced or Inoperable Gastric Cancer" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Tochigi Cancer Center" in a lesser frequency.

Most popular intervention types in "Tochigi Cancer Center" are "Drug" (24 trials), "Procedure" (4 trials), "Other" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Bortezomib" (2 trials), "Carfilzomib" (2 trials), "S-1" (2 trials) and "UFT adjuvant chemotherapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Tochigi Cancer Center" are 24 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Tochigi Cancer Center". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Tochigi Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tochigi Cancer Center, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".